Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed small cell carcinoma Any primary site or
unknown primary site Extensive or metastatic disease Lung primaries must have at least one
of the following: Contralateral hilar adenopathy Contralateral supraclavicular adenopathy
Malignant pleural effusion Distant metastases No brain metastases or CNS involvement
Stable or responding disease to prior standard therapy allowed Measurable or evaluable
disease prior to standard therapy

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 0-1 Life expectancy: Not
specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at
least 100,000/mm3 Hepatic: Bilirubin less than 2.0 mg/dL Transaminases no greater than 2
times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine
clearance at least 60 mL/min No overt renal failure Cardiovascular: Ejection fraction at
least 45% No myocardial infarction within past 6 months No congestive heart failure No
significant cardiac arrhythmia No poorly controlled hypertension Pulmonary: FEV1 and DLCO
at least 45% predicted No severe pulmonary disease Other: HIV negative No AIDS No other
prior or concurrent malignancies within the past 5 years except basal or squamous cell
skin cancer No severe medical illness (e.g., active peptic ulcer disease or brittle or
uncontrolled insulin dependent diabetes) No severe or uncontrolled psychiatric illness
(e.g., severe depression) No history of drug abuse Not pregnant or nursing Negative
pregnancy test Fertile patients must use effective contraception 3 months prior to, during
and 3 months after study No hypersensitivity to E. coli derivatives

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: 2 prior courses of
standard therapy of etoposide and a platinum analog required No other prior chemotherapy
Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: At least 3 weeks
since prior major surgery